Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Fmr LLC boosted its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 26.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 369,723 shares of the company’s stock after acquiring an additional 76,510 shares during the period. Fmr LLC owned 0.30% of Karyopharm Therapeutics worth $307,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KPTI. Point72 DIFC Ltd purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics during the second quarter valued at $143,000. Acadian Asset Management LLC purchased a new stake in Karyopharm Therapeutics in the second quarter worth $167,000. Exchange Traded Concepts LLC raised its stake in shares of Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at $494,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on KPTI shares. Piper Sandler lifted their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Down 2.2 %

Shares of NASDAQ KPTI opened at $0.64 on Friday. The company has a market cap of $80.13 million, a P/E ratio of -0.56 and a beta of 0.05. Karyopharm Therapeutics Inc. has a 52 week low of $0.63 and a 52 week high of $1.95. The business has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.85.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the business posted ($0.30) earnings per share. Equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).